Skip to content
Skip to navigation menu


Paddington’s Charity supports Biosciences Researcher

3 September 2012

Dr E Lloyd-Evans & Dr H Waller-EvansWEB

Dr Emyr Lloyd-Evans and Dr Helen Waller-Evans

Dr Emyr Lloyd-Evans has been awarded over £173,000 from the charity Action Medical Research to support three years of work into the rare childhood disease Smith-Lemli-Opitz Syndrome (SLOS). This funding augments the recent successes of the Lloyd-Evans lab who have secured over half a million pounds of funding for work related to this disease in the last 12 months. 

Characterised by severe birth defects, neurological decline and a high prevalence of autism, the multi-malformation disease SLOS is caused by an inborn error in cholesterol synthesis. The Lloyd-Evans lab has identified an important role of the lysosomal protein NPC1 in the progression of this disease. The funding from Action Medical Research will support a project which aims to clarify the mechanisms of a potential new therapy for SLOS. 

Recognising the importance of this work, this project is amongst the largest grants that Action Medical Research has funded, and consolidates the Lloyd-Evans group efforts to translate their research findings into novel therapeutic approaches in the clinic.

Dr Lloyd-Evans explains “At present, Smith-Lemli-Opitz syndrome has no viable therapy. As a result of this funding from Action Medical Research we will be able to develop and test new therapies for this disease that we are aiming to translate into a clinical therapy (in conjunction with other funding agencies).”